Table 3

Multivariable Cox regression analysis of 5-year survival of the first TNFi in AS and uSpA

	AS				uSpA
	B	SE	p Value	HR (95% CI)	B	SE	p Value	HR (95% CI)
Age (per 10 years)	0.012	0.036	0.739	1.01 (0.94 to 1.09)	0.021	0.035	0.552	1.02 (0.95 to 1.09)
Sex (ref. female)	−0.412	0.094	<0.001	0.66 (0.55 to 0.80)	−0.381	0.088	<0.001	0.68 (0.57 to 0.81)
csDMARD comedication (ref. none)	−0.349	0.094	<0.001	0.71 (0.59 to 0.85)	−0.201	0.086	0.020	0.82 (0.69 to 0.97)
TNFi type			0.037				<0.001
ADA vs IFX	−0.107	0.107	0.317	0.90 (0.73 to 1.11)	−0.365	0.111	0.001	0.69 (0.56 to 0.86)
ETN vs IFX	−0.288	0.112	0.010	0.75 (0.60 to 0.93)	−0.339	0.099	0.001	0.71 (0.59 to 0.86)
Start year 2007–2010 vs 2003–2006	0.203	0.097	0.037	1.22 (1.01 to 1.48)	0.259	0.092	0.005	1.30 (1.08 to 1.55)
Number of hospital days*	0.008	0.003	0.008	1.01 (1.00 to 1.01)	0.005	0.002	0.006	1.00 (1.00 to 1.01)
Number of outpatient visits*	0.016	0.006	0.010	1.02 (1.00 to 1.03)	0.005	0.005	0.264	1.01 (1.00 to 1.01)
Disposable income (per 1000 €)†	−0.005	0.004	0.146	0.99 (0.99 to 1.00)	−0.002	0.003	0.459	1.00 (0.99 to 1.00)
Education			0.087				0.032
10–12 years vs ≤9 years	−0.075	0.119	0.532	0.93 (0.73 to 1.17)	−0.131	0.120	0.275	0.88 (0.69 to 1.11)
>12 years vs ≤9 years	−0.253	0.134	0.060	0.78 (0.60 to 1.01)	−0.355	0.131	0.007	0.70 (0.54 to 0.91)
Missing vs ≤9 years	0.937	0.719	0.192	2.55 (0.62 to 10.4)	−10.29	102.1	0.920	0.00 (0.00 to ∞)

*During the period 2 years prior to TNFi start.
†2008 data used for patients started on TNFi in 2010, data from the year prior for all other patients.
ADA, adalimumab; AS, ankylosing spondylitis; csDMARD, conventional synthetic disease modifying antirheumatic drug; ETN, etanercept; IFX, infliximab; TNFi, tumour necrosis factor inhibitor; uSpA, undifferentiated spondyloarthritis.